Unity Biotechnology Inc

NASDAQ:UBX   3:59:58 PM EDT
1.86
+0.17 (+10.06%)
Products, Regulatory

Unity Biotechnology Announces Improvement In Visual Acuity Sustained Through 24 Weeks Following Single Dose Of UBX1325 In Phase 1 Study

Published: 11/09/2021 12:41 GMT
Unity Biotechnology Inc (UBX) - Unity Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of Ubx1325 in Phase 1 Study of Patients With Advanced Vascular Eye Disease.
Unity Biotechnology Inc - Majority of Patients With Dme Across All Doses Had Rapid Improvements in Vision.
Unity Biotechnology - Patients in Higher Dose Cohorts Showed Mean Gain of 9.5 Etdrs Letters in Bcva at 24 Weeks After Single Injection of Ubx1325.
Unity Biotechnology Inc - Majority of Wet Amd Patients Treated With Ubx1325 Showed Rapid Gains in Visual Acuity.
Unity Biotechnology Inc - Phase 2 Study in Wet Amd is Planned for First Half of 2022, With 12-week Data Expected in Second Half of Year.